10x Genomics (TXG)
(Delayed Data from NSDQ)
$13.70 USD
+0.06 (0.44%)
Updated Nov 3, 2025 04:00 PM ET
After-Market: $13.72 +0.02 (0.15%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TXG 13.70 +0.06(0.44%)
Will TXG be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for TXG
10x Genomics (TXG) Upgraded to Buy: Here's Why
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TXG
Terex upgraded to Equal Weight from Underweight at Morgan Stanley
REV Group price target lowered to $55 from $64 at Morgan Stanley
Cautious Hold Rating Amid Strategic Merger Risks for Terex and REV Group
Director’s Bold Move: Major Investment in Terex Stock
Terex price target lowered to $52 from $58 at Citi